SLC5A2 and diabetes mellitus: Several RCTs (21, 22) and a meta-analysis (23) have demonstrated that the use of SGLT2 inhibitors lowers cardiovascular mortality and reduces hospitalizations due to HF in patients irrespective of the presence of diabetes.